Anti-inflammatory properties of Septilin in lipopolysaccharide activated monocytes and macrophage

Immunopharmacology and Immunotoxicology

Volumn 33, Issue 1, 2011, Pages 55-63

  Sandeep Varma, R ^a   Ashok, G ^a   Vidyashankar, S ^a   Patki, P ^a   Nandakumar, K S ^a  

^a Himalaya Health Care   (India)

Author keywords

cycloxygenase 2; herbal immunomodulation; nitric oxide; nitric oxide synthase; phosphodiesterase 4 B; Septilin; tumor necrosis factor

Indexed keywords

DEXAMETHASONE; HERBACEOUS AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVB; SEPTILIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INTRACELLULAR SIGNALING; MACROPHAGE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL CULTURE TECHNIQUES; CELL LINE; CELL SURVIVAL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MONOCYTES; NITRIC OXIDE; PLANT EXTRACTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551603549     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923971003739236     Document Type: Article

References (52)

1. Ernst, E. Prevalence of use of complementary/alternative medi-cine: a systematic review. Bull. World. Health. Organ. 2000, 78, 252-257.
2. Spelman, K., Burns, J., Nichols, D., Winters, N., Ottersberg, S., Tenborg, M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern. Med. Rev. 2006, 11, 128-150.
3. Gemsa, D., Leser, H.G., Seitz, M., Debatin, M., Bärlin, E., Deimann, W., Kramer, W. Te role of macrophages in infam-mation. Agents. Actions. Suppl. 1982, 11, 93-114.
4. Ziegler, H.K., Stafleno, L.K., Wentworth, P. Modulation of mac-rophage Ia-expression by lipopolysaccharide. I. Induction of Ia expression in vivo. J. Immunol. 1984, 133, 1825-1835.
5. Chakravortty, D., Kumar, K.S. Interaction of lipopolysaccharide with human small intestinal lamina propria fbroblasts favors neu-trophil migration and peripheral blood mononuclear cell adhesion by the production of proinfammatory mediators and adhesion molecules. Biochim. Biophys. Acta. 1999, 1453, 261-272.
6. Yin, L.L., Zhang, W.Y., Li, M.H., Shen, J.K., Zhu, X.Z. CC 05, a novel anti-infammatory compound, exerts its efect by inhibition of cyclooxygenase-2 activity. Eur. J. Pharmacol. 2005, 520, 172-178.
7. Heiss, E., Herhaus, C, Klimo, K., Bartsch, H., Gerhäuser, C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-infammatory mechanisms. J. Biol. Chem. 2001, 276, 32008-32015.
8. Moncada, S., Palmer, R.M., Higgs, E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43, 109-142.
9. Niwa, M., Nakamura, N., Kitajima, K., Ueda, M., Tsutsumishita, Y, Futaki, S., Takaishi, Y. Benzoquinones inhibit the expression of inducible nitric oxide synthase gene. Biochem. Biophys. Res. Communi. 1997, 239, 367-371. (Pubitemid 27488970)
10. Needleman, P., Isakson, PC Te discovery and function of COX-2. J. Rheumatol. Suppl. 1997, 49, 6-8.
11. Croford, L.J., Lipsky, P.E., Brooks, P., Abramson, S.B., Simon, L.S., van de Putte, L.B. Basic biology and clinical application of specifc cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000, 43, 4-13.
12. Shu-Jing, W.U., Lean-Teik, N.G. Tetrandrine inhibits proinfam-matory cytokines, iNOS and COX-2 expression in human mono-cytic cells. Biol. Pharm. Bull. 2007, 30, 59-62.
13. Souness, J.E., Aldous, D., Sargent, C. Immunosuppressive and anti-infammatory efects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 2000, 47, 127-162.
14. Essayan, D.M. Cyclic nucleotide phosphodiesterases. J. Allergy. Clin. Immunol. 2001, 108, 671-680.
15. Celli, B. COPD, infammation and its modulation by phosphodi-esterase 4 inhibitors: time to look beyond the FEV1. Chest. 2006, 129, 5-6.
16. Kroemer, G., Martínez, C. Cytokines and autoimmune disease. Clin. Immunol. Immunopathol. 1991, 61, 275-295.
17. Medzhitov, R., Janeway, C.A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002, 296, 298-300.
18. Kim, M.S., Yi, J.M., Kim, S.H., Hong, S.H., Kim, H.M. Madimadi, Korean folk medicine, blocks TNF-alpha, IL-1beta, and IL-8 pro-duction by activated human immune cells. Cytokine. 2004, 25, 179-186.
19. Plaeger, S.F. Clinical immunology and traditional herbal medi-cines. Clin. Diag. Lab. Med. 2003, 10, 337-338.
20. Praveenkumar V., Kuttan V., Kuttan G. Immunopotenitating activ-ity of Septilin. Ind. J. Exp. Biology. 1997, 35, 1319-1323.
21. Daswani, B.R., Yegnanarayan, R. Immunomodulatory activity of septilin, a polyherbal preparation. Phytother. Res. 2002, 16, 162-165.
22. Mitra, S.K., Varma, S.R., Godavarthi, A., Nandakumar, K.S. Liv.52 regulates ethanol induced PPARgamma and TNF alpha expres-sion in HepG2 cells. Mol. Cell. Biochem. 2008, 315, 9-15.
23. Shiau, M.Y, Chiou, H.L., Lee, Y.L., Kuo, T.M., Chang, YH. Establishment of a consistent L929 bioassay system for TNF-alpha quantitation to evaluate the efect of lipopolysaccharide, phy-tomitogens and cytodiferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells. Mediators. Infamm. 2001, 10, 199-208.
24. Chakravortty, D., Kumar, K.S. Induction of cell proliferation and collagen synthesis in human small intestinal lamina propria fbroblasts by lipopolysaccharide: possible involvement of nitric oxide. Biochem. Biophys. Res. Commun. 1997, 240, 458-463.
25. Peng, X., Mosser, D.M., Adler, M.W., Rogers, T.J., Meissler, J.J. Jr, Eisenstein, T.K. Morphine enhances interleukin-12 and the pro-duction of other pro-infammatory cytokines in mouse peritoneal macrophages. J. Leukoc Biol. 2000, 68, 723-728.
26. Sorli, C.H., Zhang, H.J., Armstrong, M.B., Rajotte, R.V., Maclouf, J., Robertson, R.P. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl. Acad. Sci. U.S.A. 1998, 95, 1788-1793.
27. Méhats, C., Tanguy, G, Dallot, E., Robert, B., Rebourcet, R., Ferré, F., Leroy, M.J. Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3',5'-monophosphate (cAMP)-specifc phosphodieste-rase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology. 1999, 140, 3228-3237.
28. Klopotek, A., Hirche, F., Eder, K. PPAR gamma ligand troglita-zone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp. Biol. Med. (Maywood) 2006, 231, 1365-1372.
29. Rathore, B., Ali Mahdi, A., Nath Paul, B., Narayan Saxena, P., Kumar Das, S. Indian herbal medicines: possible potent thera-peutic agents for rheumatoid arthritis. J. Clin. Biochem. Nutr. 2007, 41, 12-17.
30. Soeken, K.L., Miller, S.A., Ernst, E. Herbal medicines for the treat-ment of rheumatoid arthritis: a systematic review. Rheumatology. (Oxford). 2003, 42, 652-659. (Pubitemid 37220874)
31. Grewal, D.S., Sharma, B.K., Shah, D.D., Sheode, J.H. Septilin and geriforte in allergic and vasomotor rhinitis Nasus A. Larynx. 1985, 12, 95-101.
32. Khanna, N., Sharma, S.B. Anti-infammatory and analgesic efect of herbal preparation: septilin. Ind. J. Med. Sci. 2001, 55, 195-202.
33. Arend, W., Dayer, J. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis. Rheum. 1990, 33, 305-315.
34. Moreland, L.W., Schif, M.H., Baumgartner, S.W., Tindall, E.A., Fleischmann, R.M., Bulpitt, K.J., Weaver, A.L., Keystone, E.C., Furst, D.E., Mease, P.J., Ruderman, E.M., Horwitz, DA., Arkfeld, D.G., Garrison, L., Burge, D.J., Blosch, C.M, Lange, M.L., McDonnell, N.D., Weinblatt, M.E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 1999, 30, 478-486.
35. Ju, H.K., Baek, S.H., An, R.B., Bae, K., Son, K.H., Kim, H.P., Kang, S.S., Lee, S.H., Son, J.K., Chang, H.W. Inhibitory efects of nardostachin on nitric oxide, prostaglandin E2, and tumor necrosis factor-alpha production in lipopolysaccharide activated macrophages. Biol. Pharm. Bull. 2003, 26, 1375-1378.
36. Chung, H.S., Kang, M., Cho, C, Parvez, S., Park, C.H., Kim, D., Oh, J., Kim, H., Shin, M., Hong, M., Kim, Y., Bae, H. Inhibition of nitric oxide and tumor necrosis factor-alpha by moutan cortex in activated mouse peritoneal macrophages. Biol. Pharm. Bull. 2007, 30, 912-916.
37. Pant N., Jain, J.C. Inducible nitric oxide synthase (iNOs) inhibitors from plant. Ind. J. Pharm. Sci. 2002, 64, 183-190.
38. Dirsch, V.M., Stuppner, H., Vollmar, A.M. Te Griess assay: suit-able for a bio-guided fractionation of anti-infammatory plant extracts? Planta. Med. 1998, 64, 423-426.
39. Chakravortty, D., Kato, Y., Sugiyama, T., Koide, N., Mu, M.M., Yoshida, T., Yokochi, T. Inhibition of caspase 3 abrogates lipopolysaccharide-induced nitric oxide production by preventing activation of NF-kappaB and c-Jun NH2-terminal kinase/stress-activated protein kinase in RAW 264.7 murine macrophage cells. Infect. Immun. 2001, 69, 1315-1321.
40. Jagetia, G.C., Rao, S.K., Baliga, M.S., Babu, K. Te evaluation of nitric oxide scavenging activity of certain herbal formulations in vitro: a preliminary study. Phytother. Res. 2004, 18, 561-565.
41. Anderson, G.D., Hauser, S.D., McGarity, K.L., Bremer, M.E., Isakson, P.C., Gregory, S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses infammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 1996, 97, 2672-2679.
42. Amin, A.R., Attur, M., Patel, R.N., Takker, G.D., Marshall, PJ., Rediske, J., Stuchin, S.A., Patel, I.R., Abramson, S.B. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-afected carti-lage. Infuence of nitric oxide. J. Clin. Invest. 1997, 99, 1231-1237.
43. Dubois, R.N., Abramson, S.B., Croford, L., Gupta, R.A., Simon, L.S., Van De Putte, L.B., Lipsky, P.E. Cyclooxygenase in biology and disease. FASEB. J. 1998, 12, 1063-1073.
44. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. New. Biol. 1971, 231, 232-235.
45. Murray, M.D., Brater, D.C. Renal toxicity of the nonsteroidal anti-infammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1993, 33, 435-465.
46. Barnes, PJ. Cyclic nucleotides and phosphodiesterases and airway function. Eur. Respir. J. 1995, 8, 457-462.
47. Teixeira, M.M., Gristwood, R.W., Cooper, N., Hellewell, P.G Phosphodiesterase (PDE)4 inhibitors: anti-infammatory drugs of the future? Trends. Pharmacol. Sci. 1997, 18, 164-171.
48. Jin, S.L., Conti, M. Induction of the cyclic nucleotide phos-phodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl. Acad. Sci. U.S.A. 2002, 99, 7628-7633.
49. Ma, D., Wu, P., Egan, R.W., Billah, M.M., Wang, P. Phosphodiesterase 4B gene transcription is activated by lipopoly-saccharide and inhibited by interleukin-10 in human monocytes. Mol. Pharmacol. 1999, 55, 50-57.
50. Sinha, B., Semmler, J., Eisenhut, T., Eigler, A., Endres, S. Enhanced tumor necrosis factor suppression and cyclic adeno-sine monophosphate accumulation by combination of phos-phodiesterase inhibitors and prostanoids. Eur. J. Immunol. 1995, 25, 147-153.
51. Perkins, DJ., Kniss, D.A. Blockade of nitric oxide formation down-regulates cyclooxygenase-2 and decreases PGE2 biosyn-thesis in macrophages. J. Leukoc Biol. 1999, 65, 792-799.
52. Skidgel, R.A., Gao, X.P., Brovkovych, V, Rahman, A., Jho, D., Predescu, S., Standiford, TJ., Malik, A.B. Nitric oxide stimulates macrophage infammatory protein-2 expression in sepsis. J. Immunol. 2002, 169, 2093-2101.